Cytomedix Announces the Publication of a New AutoloGel(tm) Case Series in the Journal...

Cytomedix Announces the Publication of a New AutoloGel(tm) Case Series in the
Journal WOUNDS

ROCKVILLE, Md., May 27, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF)
today announced the publication in WOUNDS of a paper entitled "Double impact":
Synergism in using Negative Pressure Wound Therapy with alternated applications
of Autologous Platelet-Derived Growth Factors in treating post acute surgical
wounds. This case series, authored by Mr. Leon Gurvich ANP, MS, MPH, CWS, was
conducted at the L. Weiss Memorial Hospital, Wound Healing Center in Chicago,
Illinois where Mr. Gurvich is in practice.

In the case series, four wound treatment patient cases are presented. Patients
were treated with an alternating regimen of two wound healing technologies:
Negative Pressure Wound Therapy (NPWT) and an autologous platelet rich gel,
AutoloGel(tm) intended to improve and expedite overall progression to wound
healing.

WOUNDS is the most widely read, peer-reviewed journal focusing on wound care and
wound research. Their multidisciplinary readership consists of dermatologists,
general surgeons, plastic surgeons, vascular surgeons, internal medicine/family
practitioners, podiatrists, gerontologists, researchers in industry or academia
(PhDs), orthopedic surgeons, infectious disease physicians, nurse practitioners,
and physician assistants.

"It has become increasingly apparent that AutoloGel(tm) can be used effectively
in combination with other widely used wound care products," said Martin
Rosendale, Chief Executive Officer of Cytomedix. "We are pleased that Mr.
Gurvich has been able to demonstrate the added value of alternating NPWT with
the AutoloGel(tm) System when the wound healing progression has stalled."

The article can be found online at:
http://www.woundsresearch.com/content/synergism-using-npwt-with-alternated-appli
ations-autologous-platelet-derived-growth-factors

ABOUT CYTOMEDIX

Cytomedix is a biotechnology company that develops, sells, and licenses
regenerative biological therapies, including the AutoloGel(tm) System, a device
for the production of platelet rich plasma gel. The AutoloGel(tm) System is
cleared by the Food and Drug Administration for use on a variety of exuding
wounds. Additional information regarding Cytomedix is available at:
http://www.cytomedix.com

SAFE HARBOR STATEMENT

Statements contained in this press release not relating to historical facts are
forward-looking statements that are intended to fall within the safe harbor rule
for such statements under the Private Securities Litigation Reform Act of 1995.
The information contained in the forward-looking statements is inherently
uncertain, and Cytomedix's actual results may differ materially due to a number
of factors, many of which are beyond Cytomedix's ability to predict or control,
including among others, the commercial success or acceptance by the medical
community, competitive responses, viability and effectiveness of the Company's
sales approach and overall marketing strategies, and Cytomedix's ability to
execute on its strategy to market the AutoloGel(tm) System as contemplated.
These forward-looking statements are subject to known and unknown risks and
uncertainties that could cause actual events to differ from the forward-looking
statements. More information about some of these risks and uncertainties may be
found in the reports filed with the Securities and Exchange Commission by
Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing
business and regulatory environment, thus new or unforeseen risks may arise.
Accordingly, investors should not place any reliance on forward-looking
statements as a prediction of actual results. Except as is expressly required by
the federal securities laws, Cytomedix undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new information,
changed circumstances or future events or for any other reason.

-0-
CONTACT: Cytomedix, Inc.
David Jorden, Executive Board Member
Martin Rosendale, Chief Executive Officer
240-499-2680